Inverness/Acon rapid diagnostics deal
This article was originally published in The Gray Sheet
Inverness Medical Innovations will pay $200 million to acquire the remainder of Acon Laboratories' worldwide lateral flow immunoassay rapid diagnostics business under a March 19 definitive agreement. In March 2006, Inverness purchased for $175 million the business for territories limited to the U.S., Canada, Western Europe, Australia, Israel, Japan and New Zealand. The newly acquired territories include China, Asia Pacific, Latin America, South America, the Middle East, Africa, India, Pakistan, Russia and Eastern Europe. Those markets generated about $45 million in sales in 2008. San Diego-based Acon notes that it will retain its other worldwide in vitro diagnostics businesses, including diabetes, clinical chemistry and immunoassay products. The firms expect the deal to close by April 30
You may also be interested in...
The Onyx One Clear study, evaluating the Resolute Onyx drug-eluting stent in high bleeding risk patients, met its primary endpoint at the one-year follow up.
Dozens of life science companies are working to find effective treatments for COVID-19. In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into some of the efforts that are under way on this front.
Market researcher The NPD Group identifies the few prestige beauty categories that posted sales growth in the US for the week ending 28 March. Companies that can pivot or ramp up activities in winning segments – and reach consumers digitally while they shelter at home – may fare best during the coronavirus pandemic.